Low Level Laser Treatment (LLLT)
As a non-invasive procedure, LLLT can be performed at an outpatient clinic, providing a distinct advantage over traditional laser surgery. There is no recovery time and no side effects, which makes LLLT an attractive treatment option for a variety of conditions, including:
Low Back Pain
Neck and Shoulder pain
Post-Operation Wound Healing
Since 1967, more than 2,500 studies have been conducted on the safety and effectiveness of LLLT in providing relief from pain and other symptoms. Many of these studies attest to its reliability in treating these conditions and recommend the treatment as a preferred non-invasive technique.
With 17 FDA market clearances, Erchonia laser products have been proven to safely assist patients in pain management and fat loss.
We use the Erchonia EVRL handheld unit. Harnessing the power of both red and violet cold low-level lasers, the EVRL uses low-level laser therapy (LLLT) to safely and effectively treat a broader range of conditions than many other cold lasers available today. The combination of lasers in this innovative design offers unique anti-bacterial and anti-microbial properties and can treat an extensive range of conditions.
A Clinical Study of the Effectiveness for Mitigating Pain and Improving Range of Motion with the Erchonia Low-Level Laser on Minor Neck and Shoulder Pain: July-Sept 2000
*Erchonia Corporation study submitted to the FDA and given market clearance January 2002.
One hundred patients were recruited to participate in a randomized, double-blind study of the temporary effects of the Erchonia low-level laser on ameliorating minor neck and shoulder pain and in improving range of motion. Individual subject-success criteria was defined as a 30% improvement in degree of pain from pre- to post-procedure measurement immediately following treatment. Forty out of the 50 test group subjects (80% of all test group subjects) met or exceeded the individual success criteria by demonstrating a 30% improvement in degree of pain rating from pre- to post-procedure measurement. Seven out of the 50 placebo group subjects (14% of all placebo group subjects) met or exceeded the individual success criteria by demonstrating a 30% improvement in degree of pain. Temporary improvements in pain levels for test patients were statistically significant at the p<0.05 level. Although not statistically significant, for the majority of patients, the reduction in degree of pain immediately after treatment by the laser was maintained or reduced further 24 hours post-treatment. Post-procedure linear range of motion measurements suggested significant improvements in range of motion for the right side of the neck and both right and left sides of shoulders. No adverse events were reported.
The Erchonia low-level laser is a safe and effective device for single-use temporary pain relief and improvement in range of motion for patients with chronic pain in the neck and shoulder areas originating from the conditions of osteoarthritis, muscle spasms and cervical and thoracic spine strain. This landmark study helped the Erchonia Corporation low level laser to become the first low level laser of any kind to be approved by the FDA.